US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PIMCO DYNAMIC INCOME STRATEGY FUND

24.87

+0.14000.57%

Post-market: 25.000.1299+0.52%17:38 EDT

Volume:156.15K

Turnover:3.88M

Market Cap:1.11B

PE:14.21

High:25.00

Open:24.89

Low:24.69

Close:24.73

Loading ...

Overview Company News Filings

Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

ACCESS Newswire

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine

ACCESS Newswire

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

CLEAR, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening New Locations

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025

ACCESS Newswire

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Press Release: Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

CLEAR Launches New Lanes at Portland International Airport

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

PIMCO Closed-End Fund Declares Special Year-End Distribution

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PDX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PDX\",,,,,undefined,":{"symbol":"PDX","market":"US","secType":"STK","nameCN":"PIMCO DYNAMIC INCOME STRATEGY FUND","latestPrice":24.87,"timestamp":1749844800000,"preClose":24.73,"halted":0,"volume":156149,"hourTrading":{"tag":"盘后","latestPrice":24.9999,"preClose":24.87,"latestTime":"17:38 EDT","volume":207,"amount":5173.08,"timestamp":1749850688376},"delay":0,"floatShares":0,"shares":44706949,"eps":1.75078,"marketStatus":"Market Closed","change":0.14,"latestTime":"06-13 16:00:00 EDT","open":24.89,"high":25,"low":24.69,"amount":3880767.3494240004,"amplitude":0.012535,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.75078,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1548824400000,"exchange":"NYSE","adjPreClose":24.73,"dividendRate":0.073583,"postHourTrading":{"tag":"盘后","latestPrice":24.9999,"preClose":24.87,"latestTime":"17:38 EDT","volume":207,"amount":5173.08,"timestamp":1749850688376},"volumeRatio":1.7188961976537065},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PDX\",,,,,undefined,":{"symbol":"PDX","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.7188961976537065,"shares":44706949,"dividePrice":1.83,"high":25,"amplitude":0.012535,"preClose":24.73,"low":24.69,"week52Low":19.26,"pbRate":"--","week52High":32.8807,"institutionHeld":0,"latestPrice":24.87,"eps":1.75078,"divideRate":0.073583,"volume":156149,"delay":0,"ttmEps":1.75078,"open":24.89,"prevYearClose":26.13,"prevWeekClose":24.08,"prevMonthClose":23.25,"prevQuarterClose":24.54,"fiveDayClose":24.08,"twentyDayClose":22.34,"sixtyDayClose":23.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PDX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535084331","title":"Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535084331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535084331?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166700,"startTime":"0","endTime":"0","summary":"-- SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia  Xenograft Models --. -- Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in AML Anticipated in 2025 --. -- $28.4 million in Cash and Cash Equivalents as of March 31, 2025; Additional $4.0 million Proceeds received in April 2025 through Warrant Exercises --. NEW YORK, May 13, 2025  -- SELLAS Life Sciences Group, Inc.  , a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.Presented Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference: Preclinical data suggest tha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4588","ALL","BK4533","BK4232","BK4107","BK4022","LU2355687059.USD","CR","R","OS","ORR","BK4585","BK4161","PDX","BK4097","BK4139","LU1699723380.USD","PR","BK4213","LU0985320562.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2532366308","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2532366308","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532366308?lang=en_us&edition=fundamental","pubTime":"2025-05-02 05:14","pubTimestamp":1746134040,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of March 31, 2025:. Annualized current distribution rate expressed as a percentage of NAV as of 3/31/2025. Annualized current distribution rate expressed as a percentage of Market Price as of 3/31/2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-211400749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4595","BK4516","PNF","RCS","PDO","PNI","PFL","PFN","PDI","PYN","BK4585","BK4600","PCN","BK4588","PZC","PCK","BK4023","BK4596","PCM","STRK","PAXS","PCQ","PMF","PDX","PML","PGP","PMX","PTY","PHK"],"gpt_icon":1},{"id":"2530780282","title":"Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House","url":"https://stock-news.laohu8.com/highlight/detail?id=2530780282","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530780282?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:45","pubTimestamp":1745847900,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology , a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft  models.This comprehensive program will support drug developers across a range of modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-obtains-radioactive-materials-134500788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSBR","ARKG","BK4121","PDX","BK4585","BK4544","BK4588"],"gpt_icon":0},{"id":"2530027654","title":"Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2530027654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530027654?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:28","pubTimestamp":1745843280,"startTime":"0","endTime":"0","summary":"Activated b-catenin or loss of its negative regulator adenomatous polyposis coli  is a potential biomarker for NT219 in the treatment of colorectal cancer. NT219’s mechanism of action informs how it can restore efficacy of immunotherapies and expand the patient population that can benefit from immunotherapies. REHOVOT, Israel, April 28, 2025  -- Purple Biotech Ltd.  , a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today that two posters reporting new NT219 data being presented at the American Association for Cancer Research  Annual Meeting on Sunday and Monday, April 27-28, 2025.NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or metastatic head and neck squamous cell cancer  in combination with pembrolizumab  and in combination with cetuximab .“These biomarker and mechanism data are important guides for study design, patient sel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/purple-biotech-reports-positive-nt219-122800847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443382.USD","BK4213","LU2236285917.USD","PDX","LU2456880835.USD","CRC","LU0157215616.USD","LU2237443622.USD","LU2237443978.SGD","LU1496350171.SGD","LU1366192091.USD","LU2417539215.USD","PPBT","LU0456854461.SGD","LU2237443549.SGD","BK4007","LU1366333091.USD","LU0266512127.USD","APC","LU2420271590.USD","LU0077335932.USD"],"gpt_icon":0},{"id":"2530716857","title":"Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530716857","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530716857?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:00","pubTimestamp":1745600400,"startTime":"0","endTime":"0","summary":"-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors --. \"We designed EO-1022 with several notable features, including glycan site-specific conjugation and MMAE payloads, in order to address the significant need for a novel HER3 ADC that can potentially deliver improved efficacy and safety to patients with a range of solid tumors,\" saidJoseph Ferra, President and Chief Executive Officer of Elevation Oncology. \"Today, we are excited to share preclinical proof-of-concept data for EO-1022, which indicate enhanced stability and anti-tumor activity than benchmark HER3 ADCs in the models tested in vitro and in vivo. We believe these findings support the potential of EO-1022 in treating multiple HER3-expressing cancers and look forward to progressing this program toward the clinic.\". EO-1022 elicits anti-tumor activity in in vivo models of low, medium and high HER3 expression levels, including in a patient derived xenogra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/elevation-oncology-presents-preclinical-proof-170000523.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elevation-oncology-presents-preclinical-proof-170000523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0256331488.USD","LU1721429741.USD","AFG","DAR","BK4539","LU2380233275.USD","BK4189","LU1721429402.USD","LU2308191902.HKD","BK4231","ELEV","PDX","PACI.U","BK4117","BK4107","BK4080","ADC","BK4139","LU2211817866.USD"],"gpt_icon":0},{"id":"2530168605","title":"Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2530168605","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530168605?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:00","pubTimestamp":1745600400,"startTime":"0","endTime":"0","summary":"Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms. Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026. “The breadth of data shared at AACR highlights the strength of our oncology portfolio across antibody-drug conjugates and T cell engagers, and demonstrates the novel approaches we employ using each modality,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “We’re particularly excited to share data on ZW209, the latest of our oncology nominated IND programs which has demonstrated promising anti-tumor activity in preclinical small cell lung cancer models by integrating CD28 co-stimulation into a trispecific T cell engager. We look forward to advancing ZW209 with an IND submission anticipated in the first half of 2026, while also progressing the differentiated programs in our wholly-owned pipeline.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zymeworks-presents-data-multiple-development-170000085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CDX","PDX","PK","BK4505","TIL","ZYME","BTC","BK4218","BK4181"],"gpt_icon":0},{"id":"2529098284","title":"Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine","url":"https://stock-news.laohu8.com/highlight/detail?id=2529098284","media":"ACCESS Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529098284?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology , a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of the world's first interpretable cell simulation platform. This partnership is set to revolutionize biopharma drug discovery workflows by integrating Champions' state-of-the-art multi-omic dataset with Turbine's cutting-edge virtual lab technology.By combining Champions' comprehensively annotated, clinically relevant multi-omic datasets with Turbine's virtual cell-based simulation platform and its capacity to generalize beyond training data, researchers can now conduct in silico experiments with exceptional speed and precision, covering perturbations they would otherwise be unable to investigate. This significant synergy minimizes reliance on traditional laboratory methods and enhances drug discovery initiatives, ranging from target identification to the generation of mechanistic insights, through the in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncologys-data-platform-gains-120000104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PDX","CSBR","BK4121"],"gpt_icon":0},{"id":"2523094567","title":"Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094567","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094567?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052245/0/en/Apollomics-and-LaunXP-Announce-Development-and-Commercialization-Agreement-for-Vebreltinib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDX","APLMW"],"gpt_icon":0},{"id":"2521712348","title":"CLEAR, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening New Locations","url":"https://stock-news.laohu8.com/highlight/detail?id=2521712348","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521712348?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"New enrollment locations offer convenient options for consumers to enroll or renew in TSA PreCheckNEW YORK, March  24, 2025  (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), an official TSA PreCheck enrollment ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047647/0/en/CLEAR-an-Official-TSA-PreCheck-Enrollment-Provider-Expands-Enrollment-and-Renewal-Options-by-Opening-New-Locations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0426417589.USD","LU1043141396.HKD","LU0310800965.SGD","PHX","BK4228","LU1267930227.SGD","BK4143","PT","SG9999001077.SGD","SEA","BK4585","BK4500","BHM","BK4559","LU1043141123.HKD","BK4521","SAN","IE00BFMHRM44.USD","YOU","SAT","BK4588","BK4207","BK4112","BK4209","LU1121112475.USD","DAL","BK4008","MCI","PDX","DTW","BK4213","LU0052756011.USD","MSP","PIT","BDL","DHS","LU0128525689.USD","GRR","GSP","BK4097","PSP","BK4023","BK4215","BK4539","BK4548","LU0426412945.USD","MCO","PBI","LU0994945656.USD","LU0390134368.USD"],"gpt_icon":0},{"id":"2517131151","title":"Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517131151","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517131151?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:00","pubTimestamp":1741294800,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. , a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2025, on Tuesday, March 11, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT . To join the call dial 888-506-0062  or 973-528-0011  and enter the access code 403045. A replay of the call will be available by dialing 877-481-4010  or 919-882-2331  and entering passcode:52158, or by accessing the investors section of the company's website within 72 hours.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-announce-third-quarter-210000487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","PDX","CSBR"],"gpt_icon":0},{"id":"2516327660","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2516327660","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516327660?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:22","pubTimestamp":1741044120,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of January 31, 2025:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-232200478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCM","PZC","BK4516","PAXS","PNI","PDI","PCQ","BK4595","PGP","STRK","BK4585","PFL","BK4023","PCN","PYN","PTY","PFN","BK4588","PNF","PML","PCK","BK4600","PDX","PHK","PMF","RCS","BK4596","PMX","PDO"],"gpt_icon":1},{"id":"2514303073","title":"Press Release: Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514303073","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514303073?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer  clinical trial  -. - Priced oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors -. - Issuance of new patent with claims for the use of onvansertib for treating KRAS-mut mCRC -. - Cash and equivalents of $91.7 million as of December 31, 2024, projected runway into Q1 2027 -. - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT -. SAN DIEGO, Feb. 27, 2025  -- Cardiff Oncology, Inc. , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.-- Additional clinical data from CRDF-004 trial expected in 1H 2025. Company highlights for the quarter ended December 31, 2024, and subseq","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDX","BK4139","CRDF","ORR"],"gpt_icon":0},{"id":"2509743901","title":"CLEAR Launches New Lanes at Portland International Airport","url":"https://stock-news.laohu8.com/highlight/detail?id=2509743901","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509743901?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":"PORTLAND, ORE. and NEW YORK, Feb. 07, 2025  -- Today, CLEAR , the secure identity company, is launching its identity verification technology at Portland International Airport , bringing frictionless and predictable travel experiences to Oregon. CLEAR’s launch at PDX is expected to create 53 jobs and generate over $3 million annually in local economic impact.“When we opened our new main terminal last summer, we often got asked: Will CLEAR be coming to PDX? Today, we’re excited to deliver that option for our travelers,” said Dan Pippenger, Chief Aviation Officer at Port of Portland. “With the addition of CLEAR, we’re continuing to improve and streamline the travel experience while maintaining the highest standards of safety and security.”About Port of PortlandWith three airports, four marine terminals, and five business parks, the Port of Portland is an economic engine for transforming the region into a place where everyone is welcome, empowered, and connected to the opp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clear-launches-lanes-portland-international-130000533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","BK4539","YOU","PDX"],"gpt_icon":0},{"id":"2508175053","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175053","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175053?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:51","pubTimestamp":1738619460,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of December 31, 2024:. Annualized current distribution rate expressed as a percentage of Market Price as of 12/31/2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-215100530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PAXS","PCM","PFN","PDX","PDO","PCN","PDI","RCS","PCQ","PNF","PHK","PCK","PMF","PFL","PGP","PYN","PZC","PMX","PNI","PML","PTY"],"gpt_icon":0},{"id":"2500900549","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2500900549","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500900549?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:55","pubTimestamp":1735854900,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of November 30, 2024:. Annualized current distribution rate expressed as a percentage of NAV as of 11/30/2024. Annualized current distribution rate expressed as a percentage of Market Price as of 11/30/2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-215500914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PGP","PDX","PMF","PNF","PDO","PTY","PDI","PFL","RCS","PAXS","PHK","PNI","PCN","PYN","PFN","PMX","PCM","PZC","PCK","PCQ","PML"],"gpt_icon":1},{"id":"2492207482","title":"PIMCO Closed-End Fund Declares Special Year-End Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2492207482","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492207482?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:33","pubTimestamp":1734643980,"startTime":"0","endTime":"0","summary":"Distributions may include ordinary income, net realized capital gains and/or returns of capital. Generally, a return of capital occurs when the amount distributed by the Fund includes a portion of  your investment in the Fund in addition to  your pro-rata portion of the Fund’s net income or capital gains. The Fund’s distributions in any period may be more or less than the net return earned by the Fund on its investments, and therefore should not be used as a measure of performance or confused with “yield” or “income.” A return of capital is not taxable; rather it reduces a shareholder’s tax basis in his or her shares of the Fund.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/s05UsudlQafrnlghRT6v2w--~B/aD0yMjt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/643702798dbfb61cffe8eced7add6163","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/s05UsudlQafrnlghRT6v2w--~B/aD0yMjt3PTE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/643702798dbfb61cffe8eced7add6163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-fund-declares-213300836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PDX"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PDX\",params:#limit:5,,,undefined,":[{"date":"2025-06-12","symbol":"PDX","amount":0.1334,"announcedDate":"2025-06-02","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-12","defaultRemindTime":1749735000000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-12","currency":"USD","dateTimestamp":1749700800000,"payDate":"2025-07-01"},{"date":"2025-05-12","symbol":"PDX","amount":0.1334,"announcedDate":"2025-05-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-12","defaultRemindTime":1747056600000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-02","payableDate":"2025-05-12","currency":"USD","dateTimestamp":1747022400000,"payDate":"2025-06-02"},{"date":"2025-04-11","symbol":"PDX","amount":0.1334,"announcedDate":"2025-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-11","defaultRemindTime":1744378200000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-01","payableDate":"2025-04-11","currency":"USD","dateTimestamp":1744344000000,"payDate":"2025-05-01"},{"date":"2025-03-13","symbol":"PDX","amount":0.1334,"announcedDate":"2025-03-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-13","defaultRemindTime":1741872600000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-13","currency":"USD","dateTimestamp":1741838400000,"payDate":"2025-04-01"},{"date":"2025-02-13","symbol":"PDX","amount":0.1334,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-13","defaultRemindTime":1739457000000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739422800000,"payDate":"2025-03-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-08","recordDate":"2023-12-11","paymentDate":"2024-01-02","value":0.22,"currency":"USD"},{"executeDate":"2024-03-08","recordDate":"2024-03-11","paymentDate":"2024-04-01","value":0.26,"currency":"USD"},{"executeDate":"2024-04-10","recordDate":"2024-04-11","paymentDate":"2024-05-01","value":0.1133,"currency":"USD"},{"executeDate":"2024-05-10","recordDate":"2024-05-13","paymentDate":"2024-06-03","value":0.1133,"currency":"USD"},{"executeDate":"2024-06-13","recordDate":"2024-06-13","paymentDate":"2024-07-01","value":0.1133,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PDX\",market:\"US\",delay:false,,,undefined,":{}}}